| Literature DB >> 36045810 |
Tayebeh Oghabi Bakhshaiesh1, Elahe Nazeri1, Narges Jafarbeik-Iravani1, Zainab Shirvani-Farsani2, Rezvan Esmaeili1.
Abstract
•BsmI and TaqI have association with breast cancer risk in Iranian women.•No significant associations were identified between the FokI and ApaI and breast cancer risk in Iranian women.•No association was detected between Vitamin D level and breast cancer in Iranian women.Entities:
Year: 2022 PMID: 36045810 PMCID: PMC9422222 DOI: 10.1016/j.amsu.2022.104162
Source DB: PubMed Journal: Ann Med Surg (Lond) ISSN: 2049-0801
Fig. 1The flow chart shows the detailed study selection process of meta-analysis.
The main characteristics of studies included in the VDR gene polymorphism meta-analysis.
| ID | First Author | Year | Province | Case/Control | Mean Age | Genotyping methods | Studied SNPs |
|---|---|---|---|---|---|---|---|
| 1 | Shirin Shahbazi [ | 2013 | Tehran | 140/156 | cases: 45.44 | RFLP-PCR* | BsmI (0.3723) |
| 2 | Sasan Talaneh [ | 2016 | West Azerbaijan | 90/90 | cases: 42 | RFLP-PCR | FokI (0.0004) |
| 3 | Seyed Mehdi Hashemi [ | 2017 | Cistan va Balochestan | 180/178 | cases: 47.93 | RFLP-PCR | BsmI (0.0163) |
| 4 | Hengameh Mozaffarizadeh [ | 2017 | Isfahan | 50/50 | cases: 49.61 | RFLP-PCR | BsmI (0.6283) |
| 5 | Ahmad Shahabi [ | 2017 | Mazandaran | 203/214 | cases: | RFLP-PCR | BsmI (0) |
| 6 | Sasan Talaneh [ | 2017 | West Azerbaijan | 95/71 | cases: 42 | RFLP-PCR | BsmI (0.2402) |
| 7 | Ahmad Hamta [ | 2017 | Markazi | 140/160 | cases: 51 | RFLP-PCR | ApaI |
* RFLP-PCR: Restriction fragment length polymorphism-PCR.
**P value > 0.05 is in HWE.
The main characteristics of studies included in the Vitamin D level meta-analysis.
| ID | First Author | Year | Province | Case/ | Mean Age | Detected Variables | Vitamin D Level | Vitamin D normal level | Vitamin D and Breast cancer association |
|---|---|---|---|---|---|---|---|---|---|
| 8 | Sepideh Arbabi Bidgoli [ | 2014 | Khorasan | 60/116 | cases:36.45 ± 7.02 | serum 25-hydroxi | Cases = 15.17 ± 8.15 ng/ml | 10–20 ng/ml | No |
| 9 | Seyed Mostafa Shiryazdi [ | 2015 | Yazd | 57/85 | cases:49.14 ± 12 | serum 25-hydroxy | Cases = 45.18 ng/ml | >75 nmol/L | No |
Meta-analysis and publication bias between VDR gene polymorphisms and breast cancer (BC).
| SNPs | N | Model | Test of Association | Test of Heterogeneity | Publication bias | ||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | p-value | Model | p-value | I^2 | p-value (Egger's test) | |||
| BsmI | GG vs. AA + AG | 1.0995 | [0.5786; 2.0892] | 0.77 | Random | 3e-04 | 80% | 0.8349 | |
| AA vs. AG + GG | 2.2469 | [1.3568; 3.7211] | 0.001 | Random | 0.0425 | 59% | 0.4291 | ||
| GG vs. AA | 1.9102 | [0.9020; 4.0453] | 0.09 | Random | 0.0057 | 72% | 0.7196 | ||
| 5 | GG vs. AG | 0.8913 | [0.5174; 1.5352] | 0.67 | Random | 0.0127 | 68% | 0.4569 | |
| A vs. G | 1.3103 | [0.8429; 2.0366] | 0.22 | Random | 0 | 84% | 0.7975 | ||
| ApaI | CC vs. CA + AA | 0.8542 | [0.4099; 1.7799] | 0.67 | Random | 0.0297 | 78% | – | |
| AA vs. CC + CA | 1.4388 | [0.7113; 2.9103] | 0.31 | Fixed | 0.282 | 13% | – | ||
| 2 | CC vs. AA | 1.3081 | [0.3788; 4.5171] | 0.67 | Random | 0.0979 | 63% | – | |
| CA vs. CC | 0.8274 | [0.4062; 1.6850] | 0.60 | Random | 0.0376 | 76% | – | ||
| C vs. A | 0.9626 | [0.6465; 1.4334] | 0.85 | Random | 0.0763 | 68% | – | ||
| FokI | CC vs. CT + TT | 1.057 | [0.718; 1.558] | 0.777 | Fixed | 0.522 | 0% | 0.011 | |
| CC + CT vs. TT | 1.168 | [0.732; 1.863] | 0.515 | Random | 0.001 | 74% | 0.082 | ||
| 6 | CC vs. TT | 1.021 | [0.678; 1.539] | 0.921 | Fixed | 0.387 | 4.6% | 0.007 | |
| CT vs. TT | 1.107 | [0.677; 1.809] | 0.686 | Random | 0.003 | 72.2% | 0.194 | ||
| T vs. C | 1.156 | [0.802; 1.667] | 0.515 | Random | 0.002 | 73.7% | 0.052 | ||
| CC vs. CT + TT | 0.0913 | [0.0488; 0.1708] | 0 | Fixed | 0.1213 | 58% | – | ||
| TT vs. CC + CT | 0.5568 | [0.0378; 8.1927] | 0.669 | Random | 0 | 96% | – | ||
| TaqI | 2 | CC vs. TT | 0.1174 | [0.0067; 2.0537] | 0.142 | Random | 0.0028 | 88% | – |
| CT vs. TT | 0.1241 | [0.0651; 0.2366] | 0.00001 | Fixed | 0.5098 | 0 | – | ||
| C vs. T | 0.5019 | [0.0880; 2.8614] | 0.437 | Random | 0 | 96% | – | ||
****P-value of Q-test for heterogeneity test.
N: Number of studies included in the meta-analysis.
OR: odds ratio.
95%CI: 95% confidence interval.
Fig. 2The forest plots for the association between the BsmI and TaqI polymorphisms and BC risk. BsmI: AA vs. AG + GG (A), TaqI: CC vs. CT + TT (B), CT vs. TT (C).
Fig. 3Egger's funnel plot on publication bias for the association between the BsmI and TaqI polymorphisms and BC risk. BsmI: AA vs. AG + GG (A), TaqI: CC vs. CT + TT (B), CT vs. TT (C).
Fig. 4Sensitivity analysis for studies on BsmI polymorphism and BC risk.